Based on the findings presented in this manuscript, we aim to include sarcopenia and frailty in the decision-making processes regarding bladder cancer patients, using low ALT values as a marker for sarcopenia, frailty, and shortened survival. The gene discussed is GPT; the disease is sarcopenia.